Antonio Craxì

University of Palermo

Viale delle Scienza

Palermo, 90128

Italy

SCHOLARLY PAPERS

5

DOWNLOADS

118

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (5)

1.

Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy

CEIS Working Paper No. 308
Number of pages: 18 Posted: 18 Feb 2014 Last Revised: 19 Feb 2014
University of Rome Tor Vergata - Centre for International Studies on Economic Growth (CEIS), University of Rome Tor Vergata - Centre for International Studies on Economic Growth (CEIS), University of Rome Tor Vergata, Catholic University of the Sacred Heart, Rome, University of Catania and University of Palermo
Downloads 77 (345,816)
Citation 2

Abstract:

Loading...

Cost of Illness, Chronic Hepatitis, Forecast, New HCV treatment

2.

PNPLA3 Rs738409 C>G Variant Predicts Liver-Related Outcomes in Patients with Non-Alcoholic Fatty Liver Disease

Number of pages: 38 Posted: 08 Mar 2019
University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), University of Palermo, University of Palermo, University of Palermo, University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), University of Palermo, University of Palermo, University of Palermo, Università "Alma Mater", University of Palermo and University of Palermo
Downloads 22 (564,288)

Abstract:

Loading...

NAFLD, NASH, PNPLA3, Cirrhosis, Decompensation, HCC, Death

3.

PCSK9 rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD

Number of pages: 34 Posted: 19 May 2020
University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), AstraZeneca Pharmaceuticals - Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Parma - Dipartimento di Economia, University of Gothenburg - Department of Molecular and Clinical Medicine, University of Eastern Finland - Department of Medicine, AstraZeneca Pharmaceuticals - Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca Pharmaceuticals - Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Florence - Department of Experimental and Clinical Medicine, University of Eastern Finland - Department of Medicine, affiliation not provided to SSRN, AstraZeneca Pharmaceuticals - IMED Biotech Unit, University of Palermo, University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), Magna Graecia University of Catanzaro - Department of Experimental and Clinical Medicine, University of Palermo, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - General Medicine and Metabolic Diseases, University of Milan - Department of Pathophysiology and Transplantation, University of Gothenburg and University of Palermo
Downloads 9 (652,690)

Abstract:

Loading...

NASH, NAFLD, FIBROSIS, PCSK9

4.

Optimization of Hepatitis C Virus Screening Strategies by Birth Cohort in Italy

Number of pages: 31 Posted: 13 Aug 2019
Istituto Superiore di Sanità - Center for Global Health, Center for Disease Analysis Foundation, Center for Disease Analysis Foundation, University of Rome Tor Vergata, University of Milan, University of Palermo, Istituto Superiore di Sanità, Istituto Superiore di Sanità - Center for Global Health, Center for Disease Analysis Foundation, University of Palermo, University of Rome Tor Vergata - Centre for International Studies on Economic Growth (CEIS) and affiliation not provided to SSRN
Downloads 8 (659,911)

Abstract:

Loading...

cost-effectiveness, HCV, screening, WHO Targets

5.

Serum Coding and Non-Coding RNAs as Biomarkers of NAFLD and Fibrosis Severity

Number of pages: 43 Posted: 28 Sep 2018
University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Department of Clinical and Experimental Medicine, University of Palermo, University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Genome and Complex Systems BioMedicine, Magna Graecia University of Catanzaro - Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro - Department of Experimental and Clinical Medicine, University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), University of Palermo - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Department of Clinical and Experimental Medicine, University of Catania - Department of Clinical and Experimental Medicine, University of Palermo, University of Catania - Genome and Complex Systems BioMedicine, University of Catania - Department of Clinical and Experimental Medicine and University of Catania - Department of Clinical and Experimental Medicine
Downloads 2 (707,681)

Abstract:

Loading...

NASH, FIBROSIS, RNA, HepG2, DIAGNOSIS, LIQUID-BIOPSY